Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 64% Improvement Relative Risk Esper et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ+AZ beneficial for COVID-19? Prospective study of 636 patients in Brazil Lower hospitalization with HCQ+AZ (p=0.024) Esper et al., Prevent Senior Institute, São Paulo, Brazil Favors HCQ Favors control
Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine
Esper et al., Prevent Senior Institute, São Paulo, Brazil (Preprint)
Esper et al., Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by.., Prevent Senior Institute, São Paulo, Brazil (Preprint)
Apr 2020   Source   PDF  
  All Studies   Meta
636 patients. HCQ+AZ reduced hospitalization 79% when used within 7 days (65% overall). Non-randomized.
risk of hospitalization, 64.0% lower, RR 0.36, p = 0.02, treatment 8 of 412 (1.9%), control 12 of 224 (5.4%), NNT 29.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Esper et al., 15 Apr 2020, prospective, Brazil, preprint, 15 authors, average treatment delay 5.2 days, dosage 800mg day 1, 400mg days 2-7, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine Rodrigo Barbosa Esper M.D., Ph.D., Rafael Souza da Silva M.D., Fernando Teiichi Costa Oikawa M.D., Ph.D., Marcelo Machado Castro M.D., Alvaro Razuk-Filho M.D., Ph.D., Pedro Benedito Batista Junior M.D., Sergio Wilhelm Lotze M.D., Cleber Nunes da Rocha M.D., Roberto de Sá Cunha Filho M.D., Saulo Emanuel Barbosa de Oliveira M.D, Philipe Leitão Ribeiro, M.D., Valéria Cristina Vigar Martins M.D., Fernando Silva Braga Bueno M.D., Priscila Ligeiro Gonçalves Esper M.D., Eduardo Fagundes Parrillo M.D. Affiliation/institution: Prevent Senior Institute, São Paulo, Brazil Corresponding Author: Rodrigo Barbosa Esper M.D., Ph.D. Avenida Lourenço Marques, n 158, São Paulo – Brazil ZIP CODE: 04547-100 Phone: +55 11 999869306 Word Count: 4803 The Ethics Committee approved study number - CONEP/Plataforma Brasil CAAE: 30586520.9.0000.0008 (Número Parecer:3.968.699) Identifier: NCT04348474 1 Abstract Background: Telemedicine can facilitate patient’s assessment with initial flu-like symptoms in the COVID-19 pandemic, moreover it promotes social isolation. Hydroxychloroquine and azithromycin are associated with reduction in COVID-19 patients' viral load. This study aims to assess whether empirical prescription of hydroxychloroquine and azithromycin for patients with suspected COVID-19 is associated with less need for hospitalization Methods: A telemedicine team evaluated suspected contraindications COVID-19 were detected, outpatients treatment with with flu-like symptoms, hydroxychloroquine if no and azithromycin was prescribed after consent from subjects. Patients were monitored daily by telemedicine appointments. Results: Of the 636 symptomatic outpatients, 412 started treatment with hydroxychloroquine and azithromycin and 224 refused medications (control group). Need for hospitalization was 1.9% in the treatment group and 5.4% in the control group (2.8 times greater) and number needed to treat was 28 (NNT = 28). In those who started treatment before versus after the seventh day of symptoms, the need for hospitalization was 1.17% and 3.2%, respectively. Conclusion: Empirical treatment with hydroxychloroquine associated with azithromycin for suspected cases of COVID-19 infection reduces the need for hospitalization (p< 0.001). Funding: this study does not have any type of funding Keywords: SARS-CoV-2; COVID-19; hydroxychloroquine; azithromycin; telemedicine, pandemic. 2 1. Background In the past two decades, severe acute respiratory syndromes have been one of the most critical threats to global health. Coronaviruses (Mers-CoV, SARS-Cov) are virus that may affect humans and cause severe infections and deaths worldwide (1). In December 2019, a new Beta-coronavirus, named SARS-CoV-2, was associated with a set of respiratory tract infections in Wuhan, Hubei province in China, and spread rapidly across continents (2). According to the World Health Organization (WHO), the outbreak was declared a public health emergency of international interest on January 30, 2020 and on March 11, WHO announced COVID-19 outbreak a pandemic (3). Patient’s clinical characteristics from China revealed that comorbities such as diabetes, hypertension and others cardiovascular diseases were related to poor outcomes and high death rates, with three to four times more chances..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop